<DOC>
	<DOC>NCT01324583</DOC>
	<brief_summary>Primary Objective: - To assess the tolerability at global doses Secondary Objectives: - Safety - Pharmacokinetics - Efficacy</brief_summary>
	<brief_title>Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The duration of screening within 28 days, treatment 3 weeks/cycle and follow-up 30 days after the last cabazitaxel administration.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Inclusion criteria : I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that is refractory to hormone therapy (received prior castration by orchiectomy and/or internal medicine, and documented progression of disease or relapse) who has previously been treated with docetaxel. I 02. Signed informed consent prior to beginning protocol specific procedures. I 03. Patients with PSA &gt;20 ng/mL at screening. Exclusion criteria: E 01. Age &lt;20 and &gt;74 E 02. ECOG performance status ≥2. E 03. Prior surgery ≤4 weeks of registration in the study. E 04. Active secondary cancer including prior malignancy from which the patient has been diseasefree for ≤5 years (However, adequately treated superficial basal cell skin cancer before 4 weeks prior to registration can be eligible to the study) E 05. Inadequate organ function including: Neutrophils &lt;2.0 x 109/L Platelets &lt;100 x 109/L Hemoglobin &lt;9.0 g/dL (transfusion prohibition within 14 days before registration) Creatinine &gt;1.5 mg/dL. Total bilirubin &gt;1.5 times the upper normal limits of the institutional norms ALT/AST &gt;1.5 times the upper normal limits of the institutional norms E 06. Previous treatment with &lt;225 mg/m2 cumulative dose of Taxotere® (or docetaxel). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>